<DOC>
	<DOCNO>NCT02434666</DOCNO>
	<brief_summary>This long-term-safety roll-over extension study Phase II Study ( Protocol CPC-001-07 ) .</brief_summary>
	<brief_title>Long Term Extension Safety Study Patients With Dementia Alzheimer 's Type Who Completed Study CPC-001-07</brief_title>
	<detailed_description>This long-term-safety roll-over extension study Phase II Study ( Protocol CPC-001-07 ) . Patients safely complete 12-week maintenance phase Study CPC-001-07 eligible admission . Subjects remain CPC-201 MTD determine Study CPC-001-07 . The dose CPC-201 increase 15 mg/day ( administer Study CPC-001-07 ) 20mg/day start Day1 . For patient tolerate 20mg/day CPC-201 , dose CPC-201will decrease previously tolerate level 15mg/day . This protocol allow increase patient ' MTD CPC-201 , previously determine Phase II Study ( CPC-001-07 protocol ) , 5mg 10mg increment maximum 60 mg/day start Day7 Month 3 visit extension protocol per Investigator 's judgment patient 's tolerability . This extension study intend continue enrol patient 6 month unless medically contraindicate . Patients may withdraw study time . Upon termination study , patient return original daily donepezil dose 10 mg/day continue receive CPC-201 mg/day one final week .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>1 . Have sign Institutional Review Board ( IRB ) approve informed consent document indicate understand purpose procedure require study willing participate study comply study procedure restriction . Informed consent must obtain patient and/or designate representative prior initiate procedure study . 2 . Have safely complete 12 week maintenance phase CPC00107 study . 1 . Renal hepatic dysfunction : Total Bilirubin : &gt; 1.5 x UNL AST : &gt; 2.5 x UNL ALT : &gt; 2.5 x UNL Serum Creatinine : &gt; 1.5 x UNL Creatinine Clearance : &lt; 30 mL/min ( calculate Cockcroft Gault equation ) 2 . History presence myasthenia . 3 . ECG finding : Complete Left Bundle Branch Block ; Ventricular pacing ; 2nd degree 3rd degree AV block ; Atrial fibrillation atrial flutter ; HR &lt; 45 &gt; 100 ; PR &gt; 220 msec ; QTcF &gt; 450 msec male , &gt; 470 msec female 4 . Patients consider unlikely cooperate study , and/or poor compliance anticipate investigator . 5 . Any clinically relevant acute chronic disease could interfere patient ' safety trial , expose undue risk , could interfere study objective .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>